DONATE
FOR PHYSICIANS
HEALTH AND NUTRITION
ETHICAL RESEARCH & EDUCATION
MEDIA CENTER
LEGISLATIVE FOCUS
CLINICAL RESEARCH
EDUCATIONAL LITERATURE
MEMBERSHIP
SHOP

Connect with Us

 

 

The Physicians Committee



Alcoholism and mental illness: overlapping diseases requiring a renewed focus

This is an Accepted Manuscript of an article published in Mental Health and Substance Use on June 17, 2014, available online: http://www.tandfonline.com/ 10.1080/17523281.2014.939220

Abstract

Alcohol addiction and psychiatric disorders frequently occur together, and individuals affected by both conditions represent a unique patient population in need of specialized treatment. Decades of research have pointed to promising prospective therapeutic options, yet no standardized diagnostic measures or treatment regimens are available for clinicians or their patients. As a result, patients with both alcohol abuse and mental disorders frequently do not receive specialized treatment that addresses both conditions. Moreover, a great deal of research regarding alcohol use disorder treatment has failed to include patients with co-occurring mental illnesses. To address this serious public health concern, a renewed focus on large-scale trials is required to examine the benefits of various therapeutic practices and delivery methods in the mentally ill, alcohol-dependent population. This commentary will provide a brief overview of the diagnostic and therapeutic challenges associated with treating dually diagnosed individuals, the state of current research strategies, and a potential roadmap for improving the future of research in this field.

Key words: Alcohol use, mental health, comorbidity, intervention, dual diagnosis

The scope of the problem

Alcohol abuse and alcohol dependence are two conditions characterized as alcohol use disorders. Alcohol abuse is defined as “continued drinking despite negative consequences and the inability to fulfill responsibilities”.  Alcohol dependence, on the other hand, is characterized by a craving for and possibly physical dependence on alcohol, an inability to control one’s drinking, and an increasing tolerance to the effects of alcohol.  1 Alcohol use disorders remain a substantial public health concern, due to the many physical, psychological, and social effects of alcohol abuse. Harmful drinking contributes to disorders of the heart, liver, and gastrointestinal tract, as well as many cancers, and leads to over 2.5 million deaths worldwide annually.2 Infectious diseases such as HIV and other sexually transmitted infections have been linked with alcohol abuse, stemming from risky behavior and possibly from alcohol-induced compromise of the immune system.2

However, alcohol use disorders do not exist in isolation. Among the most common complications are neuropsychiatric disorders. According to the Substance Abuse and Mental Health Services Administration, at least 6.8 million adults suffered both mental illness and substance abuse issues in 2011 (SAMHSA).3 Individuals with an alcohol use disorder are up to three times more likely than unaffected individuals to suffer from an anxiety disorder, and nearly four times more likely to suffer a major depressive episode.4, 5 In turn, co-morbid mental illness complicates substance dependence treatment.

Patients with anxiety disorders may be less likely to seek needed treatment for alcohol dependence.6 Those who do undergo addiction treatment may be more likely than alcohol dependent patients without mental illness to drop out of treatment or to relapse upon completion.7-10 Similarly, the presence and severity of depressive symptoms strongly influences the length of time to relapse following treatment for alcohol addiction.7-9, 11-13 Post-traumatic stress disorder (PTSD) is highly comorbid with alcohol dependence.14, 15  Abstinent patients suffering from both alcohol use disorders and PTSD tend to relapse faster than those with other DSM-Axis I psychiatric disorders.14

In short, there is a great need to understand how to manage the intersection of alcohol problems and mental illness. Unfortunately, despite years of effort, diagnosis and treatment of mental illness or substance abuse issues alone remains difficult, and research has not adequately untangled the two. As a result, for patients with problems in both domains, we do not yet know what sort of treatment is most effective.

Diagnostic and therapeutic challenges

Individuals suffering from both alcohol use disorders and mental illness are likely to encounter one of three types of health care professionals: primary care providers, mental health professionals, or addiction treatment specialists. Unfortunately, primary care providers are unable to devote large amounts of one-on-one time with individual patients. Mental health providers and addiction specialists can offer specialized care for mental illness or alcohol use disorders, respectively, but may lack the expertise to diagnose or treat a comorbid disorder. 16

A number of different treatment permutations exist. The most common model of treatment for individuals suffering both alcohol use disorders and mental illness is sequential treatment. Commonly, the addiction is treat first, and once abstinence is obtained the psychiatric symptoms will be addressed. Alternatively, parallel treatment, in which a patient receives treatment for both addiction and mental illness simultaneously.  In both parallel and sequential treatment models, mental health treatment and addiction treatment are typicall provided by separate sets of specialists who may or may not coordinate care. Integrated treatment can address both substance abuse and mental health issues simultaneously, and often involves health care professionals trained to treat both mental illness and addiction. 16

With many individuals with alcohol use disorders suffering co-occurring mental illnesses, and so many possible permutations with regard to therapies, developing firm diagnostic standards for co-morbid mental illness and standardized treatment regimens should be a priority. Diagnostically, physicians face challenges in determining whether heavy alcohol consumption contributes to or arises from a psychiatric disorder, or whether alcohol abuse and mental illness are simply co-morbid conditions.17 Moreover, a number of unique considerations must be addressed in developing a treatment plan for the mentally ill alcohol addict. Many medications have physical side effects when taken with alcohol. Mental illness and alcohol use may impair the patient’s ability to manage medications on his or her own. Psychosocial intervention may aid in treatment of mental illness and  provide needed support once alcohol consumption has ceased.17

Current status of dual diagnosis research

Several comprehensive reviews of research studies examining models of treatment for dually diagnosed patients have been published in recent years 18, 19. While all of the studies discussed in this section include participants with alcohol use disorders, many include patients with other substance abuse disorders as well. This is a common theme in the literature surrounding treatment of comorbid mental illness and substance abuse disorders, and represents a potential pitfall of current research strategies.

While a number of approaches have demonstrated promising results in both substance abuse and mental health outcomes, differences in study length, number of sessions provided to participants, and inclusion criteria make it difficult to draw helpful conclusions from these data as a whole.

Individual counseling, consisting of either motivation interviewing or cognitive behavioral therapy, has produced inconsistent results. Several short-term studies (fewer than 12 months) examining the effect of multiple individual counseling sessions on abstinence generally failed to reduce substance use long term.20-22 One study that provided schizophrenic substance abuse patients an integrated treatment program, including cognitive behavioral therapy, motivational interviewing, and family intervention for 9 months found decreased relapse rates at 12 months and decreased negative symptoms at 9 and 18 months.23

Group counseling represents an alternative to individual counseling that may still incorporate cognitive behavioral techniques. While the specifics of group counseling programs studied thus far vary, they all typically provide education and peer support, as well as tools for managing both mental and substance abuse disorders.18  A more recent short-term study of the efficacy of group cognitive behavioral therapy for depressed substance abuse patients showed improved mental health and abstinence, but without any significant difference from control patients.24  Double Trouble in Recovery is a 12 step-based dual-focus mutual aid group designed for adults with dual diagnoses.

Results from this study report improvement in substance abuse outcome but not psychiatric outcome.25 Seeking Safety and Creating Change are two group behavioral therapy models for individuals suffering from both PTSD and substance abuse disorders. Both have shown promise in treating this particular cohort of patients. 26-28

Case management is a set of  “intensive, team-based, multidisciplinary, out-reach oriented, clinically coordinated services, usually involving the model assertive community treatment”.18 Eleven studies reviewed by Drake et. al., published between 1991 and 2006, reported inconsistent results in terms of substance abuse and mental health outcomes.18, 29-39 However, several studies reported positive outcomes in other areas, such as decreased hospitalizations, improved financial functioning, and overall improved stability and global functioning.

Studies of integrated versus non-integrated residential treatment program have demonstrated that the integrated residential approach leads to increased abstinence and decreased relapse rates.18, 40-44 Overall, the data suggest that longer-term treatment resulted in better substance abuse outcomes 18, 40. While mental health outcomes were inconsistent, several studies reported fewer psychiatric symptoms in patients who received integrated inpatient care. 41, 44, 45 A more recent study indicated that male veterans with dual diagnoses respond well to inpatient substance abuse treatment, but mental health outcomes tend to be less positive.46

As an alternative to residential treatment programs, intensive outpatient programs typically provide treatment for several hours on several days throughout the week. However, relatively few studies have explored this treatment approach, and results are inconsistent.18, 47

Finally, in addition to various counseling and behavioral treatment techniques, medications may be prescribed to manage alcohol cravings and mental illness symptoms.  Despite over two decades of research into pharmacological treatment of alcohol addiction, only three medications are FDA-approved. Disulfiram induces aversion to alcohol by inhibiting alcohol metabolism in such a way that toxic intermediates accumulate in the body and produce unpleasant side effects.48 However, there is a possibility of severe side effects and potentially serious drug interactions, and its therapeutic benefit is inconsistent at best, so it is not widely prescribed.49

Naltrexone, a mu opioid receptor antagonist, likely reduces the urge to drink by interfering with the dopamine reward system.48, 50-52 Among the more serious side effects associated with naltrexone are hepatitis and liver failure.48 Although clinical results demonstrate inconsistency in the outcome of naltrexone treatment, some patients are less likely to engage in heavy drinking and have longer time to relapse.[53] The effect of naltrexone wanes following discontinuation of the drug.54, 55

Finally, the most effective medication currently approved for the treatment of alcohol addiction is acamprosate.48 However, to optimize efficacy, the medication is best prescribed to abstinent patients who have undergone detoxification.56, 57 A number of other compounds, such as nalmefene, topirimate, and ondansetron, have shown promise in the treatment of alcohol use disorders, though none has been approved by the FDA for that use.48, 58 

Although naltrexone and acamprosate were developed using animal models, the paucity of new medications coming to market, despite decades of research, is indicative of the shortcomings of current pharmacological development approaches. Moreover, a number of animal models have been developed to try to replicate alcohol addiction and anxiety, depression, stress, or PTSD for the purpose of understanding mechanisms of addiction and mental illness or testing candidate therapeutics 59-66.

These models have major limitations. Unlike humans, laboratory animals are selectively bred for alcohol preference and are trained to consume high doses of ethanol for pre-determined time periods. 59-62 These methods are employed to encourage animals to consume a specific amount of substance in a particular timeframe, a motivation that is distinct from those that drive human consumption of alcohol. In other models of alcoholism, animals do not willingly consume alcohol at all, but are rather injected intraperitoneally or subcutaneously, or receive ethanol via gavage or intubation. 67-69

Moreover, due to species-specific differences in metabolism and scale, the quantity of alcohol consumed by laboratory animals does not easily translate to realistic quantities consumed by adult humans 70. For example, in a model of binge drinking in rats, animals consumed doses of alcohol of 5g/kg body weight just in the first of several doses, administered every 8 hours for four days.64 This is the equivalent of an adult human consuming about 25 drinks in one sitting.71

Depression- or anxiety-like symptoms can be induced in animals by conditioned alcohol dependence or application of chronic stress.59, 72, 73 But the obvious biological and social differences between humans and other animals preclude a meaningful comparison of behavioral stress in laboratory animals to mental illness in humans. 59, 62, 63

While medications can be administered to animals bred to model alcohol addiction, animal data on safety or efficacy may or may not apply to humans, and there is no way to test the combination of medication and psychosocial therapy in these animals, rendering the models not only artificial, but extremely limited as well. Alcoholism is a uniquely human disease, and alcohol abuse disorders combined with various, and potentially overlapping, mental illnesses are too complex to reduce to an animal model.

Optimizing research and treatment strategies

The path forward is clear.  There must be a comprehensive approach to treatment based upon data gathered from people with alcohol use disorders. While a number of therapeutic approaches, such as those discussed above, have shown promise in treating patients with alcohol abuse disorders and mental illness, more research is required. Many researchers and health providers seem to have consolidated all substance abuse issues into a single category, and this may contribute to the lack of progress in developing effective treatments for patients with comorbid alcohol abuse disorders and mental illness.

Large, prospective studies examining individual and group therapy methods specifically in patients with alcohol abuse disorders will allow researchers to determine how to address this specific substance abuse disorder, which may require a different approach than other substance abuse issues. Moreover, separating trials by mental illness may prove helpful as well, as different mental illnesses will likely respond well to different types of treatment. A number of unique therapy-delivery strategies, such as individualized assessments or self-delivered computer-based support have shown promise as well, and should be further explored.74, 75

However, both mental illness and addiction are long-term health issues. Determining whether short- or long-term treatment strategies are most effective, and how best to implement such strategies in such as way as to be cost-effective for both patient and provider presents another area of necessary research.

There is room for a great deal of research in the field of comorbid alcohol abuse and mental health issues. Unfortunately, the most limiting factor is the availability of funding for such research. Ultimately, large funding bodies, such as the National Institute of Alcohol Abuse and Alcoholism in the United States, must be pushed to shift their funding strategies to favor these human-based intervention and treatment strategies. Only by conducting human-based interventional trials that can account for the complexity of human biology and behavior will our research produce results that may offer hope to the millions of individuals seeking to overcome the combined hurdles of alcohol abuse and mental illness.

References

  1. Petrakis, I.L., et al., Comorbidity of Alcoholism and Psychiatric Disorders: An Overview. Alcohol and Comorbid Mental Health Disorders, 2002. 26(2): p. 81-89.
  2. WHO. Alcohol. 2011  [cited 2013 29 October]; Available from: http://www.who.int/mediacentre/factsheets/fs349/en/.
  3. Data Spotlight. 2013; Available from: http://samhsa.gov/data/spotlight/spot111-adults-mental-illness-substance-use-disorder.pdf.
  4. Agosti, V. and F.R. Levin, The effects of alcohol and drug dependence on the course of depression. Am J Addict, 2006. 15(1): p. 71-5.
  5. Anthenelli, R.M., Focus on: comorbid mental health disorders. Alcohol Res Health, 2010. 33(1): p. 109-17.
  6. Book, S.W., et al., Social anxiety impacts willingness to participate in addiction treatment. Addict Behav, 2009. 34(5): p. 474-6.
  7. Boschloo, L., et al., Comorbidity and risk indicators for alcohol use disorders among persons with anxiety and/or depressive disorders: findings from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord, 2011. 131(1-3): p. 233-42.
  8. Boschloo, L., et al., Predictors of the 2-year recurrence and persistence of alcohol dependence. Addiction, 2012. 107(9): p. 1639-40.
  9. Haver, B. and R. Gjestad, Phobic anxiety and depression as predictor variables for treatment outcome. A LISREL analysis on treated female alcoholics. Nord J Psychiatry, 2005. 59(1): p. 25-30.
  10. Kushner, M.G., et al., Follow-up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients. Alcohol Clin Exp Res, 2005. 29(8): p. 1432-43.
  11. DeVido, J.J. and R.D. Weiss, Treatment of the depressed alcoholic patient. Curr Psychiatry Rep, 2012. 14(6): p. 610-8.
  12. Greenfield, S.F., et al., The effect of depression on return to drinking: a prospective study. Arch Gen Psychiatry, 1998. 55(3): p. 259-65.
  13. Samet, S., et al., Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence. Addiction, 2013. 108(1): p. 115-23.
  14. Foa, E.B., et al., Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. JAMA, 2013. 310(5): p. 488-95.
  15. Kessler, R.C., et al., Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 2005. 62(6): p. 617-27.
  16. Assessment and Treatment of Patients with Coexisting Mental Illness and Alcohol and Other Drug Abuse. 1994, Rockville MD.
  17. Shivani R., R.J.G., and Robert M. Anthenelli, Alcoholism and Psychiatric Disorders: Diagnostic Challenges. Alcohol and Comorbid Mental Health Disorders, 2002. 26(2).
  18. Drake, R.E., E.L. O'Neal, and M.A. Wallach, A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat, 2008. 34(1): p. 123-38.
  19. Hobbs, J.D., et al., Meta-analysis of supplemental treatment for depressive and anxiety disorders in patients being treated for alcohol dependence. Am J Addict, 2011. 20(4): p. 319-29.
  20. Graeber, D.A., et al., A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J, 2003. 39(3): p. 189-202.
  21. Baker, A., et al., Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial. Br J Psychiatry, 2006. 188: p. 439-48.
  22. Kavanagh, D.J., et al., A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev, 2004. 23(2): p. 151-5.
  23. Barrowclough, C., et al., Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry, 2001. 158(10): p. 1706-13.
  24. Hunter, S.B., et al., Treating depression and substance use: a randomized controlled trial. J Subst Abuse Treat, 2012. 43(2): p. 137-51.
  25. Magura, S., et al., Dual-focus mutual aid for co-occurring disorders: a quasi-experimental outcome evaluation study. Am J Drug Alcohol Abuse, 2008. 34(1): p. 61-74.
  26. Najavits, L.M. and K.M. Johnson, Pilot study of Creating Change, a new past-focused model for PTSD and substance abuse. Am J Addict, 2014.
  27. Najavits, L.M., et al., Seeking Safety plus Exposure Therapy: an outcome study on dual diagnosis men. J Psychoactive Drugs, 2005. 37(4): p. 425-35.
  28. Najavits, L.M., et al., "Seeking safety": outcome of a new cognitive-behavioral psychotherapy for women with posttraumatic stress disorder and substance dependence. J Trauma Stress, 1998. 11(3): p. 437-56.
  29. Drake, R.E., et al., Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. Am J Orthopsychiatry, 1998. 68(2): p. 201-15.
  30. Calsyn, R.J., et al., Impact of assertive community treatment and client characteristics on criminal justice outcomes in dual disorder homeless individuals. Crim Behav Ment Health, 2005. 15(4): p. 236-48.
  31. Morse, G.A., et al., Treating homeless clients with severe mental illness and substance use disorders: costs and outcomes. Community Ment Health J, 2006. 42(4): p. 377-404.
  32. Mangrum, L.F., R.T. Spence, and M. Lopez, Integrated versus parallel treatment of co-occurring psychiatric and substance use disorders. J Subst Abuse Treat, 2006. 30(1): p. 79-84.
  33. Drake, R.E., et al., Integrated treatment for dually diagnosed homeless adults. J Nerv Ment Dis, 1997. 185(5): p. 298-305.
  34. McHugo, G.J., et al., Fidelity to assertive community treatment and client outcomes in the New Hampshire dual disorders study. Psychiatr Serv, 1999. 50(6): p. 818-24.
  35. Essock, S.M., et al., Comparison of ACT and standard case management for delivering integrated treatment for co-occurring disorders. Psychiatr Serv, 2006. 57(2): p. 185-96.
  36. Ho, A.P., et al., Achieving effective treatment of patients with chronic psychotic illness and comorbid substance dependence. Am J Psychiatry, 1999. 156(11): p. 1765-70.
  37. Jerrell, J.M. and M.S. Ridgely, Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. J Nerv Ment Dis, 1995. 183(9): p. 566-76.
  38. Jerrell, J.M. and M.S. Ridgely, Impact of robustness of program implementation on outcomes of clients in dual diagnosis programs. Psychiatr Serv, 1999. 50(1): p. 109-12.
  39. Lehman, A.F., et al., Rehabilitation for adults with severe mental illness and substance use disorders. A clinical trial. J Nerv Ment Dis, 1993. 181(2): p. 86-90.
  40. Brunette, M.F., et al., A comparison of long-term and short-term residential treatment programs for dual diagnosis patients. Psychiatr Serv, 2001. 52(4): p. 526-8.
  41. De Leon, G., et al., Modified therapeutic community for homeless mentally ill chemical abusers: treatment outcomes. Am J Drug Alcohol Abuse, 2000. 26(3): p. 461-80.
  42. Moggi, F., et al., Dual diagnosis patients in substance abuse treatment: relationship of general coping and substance-specific coping to 1-year outcomes. Addiction, 1999. 94(12): p. 1805-16.
  43. Sacks, S., et al., Enhanced outpatient treatment for co-occurring disorders: main outcomes. J Subst Abuse Treat, 2008. 34(1): p. 48-60.
  44. Timko, C. and J.M. Sempel, Intensity of acute services, self-help attendance and one-year outcomes among dual diagnosis patients. J Stud Alcohol, 2004. 65(2): p. 274-82.
  45. Nuttbrock, L.A., et al., Outcomes of homeless mentally ill chemical abusers in community residences and a therapeutic community. Psychiatr Serv, 1998. 49(1): p. 68-76.
  46. Boden, M.T. and R. Moos, Dually diagnosed patients' responses to substance use disorder treatment. J Subst Abuse Treat, 2009. 37(4): p. 335-45.
  47. Burnam, M.A., et al., An experimental evaluation of residential and nonresidential treatment for dually diagnosed homeless adults. J Addict Dis, 1995. 14(4): p. 111-34.
  48. Collins, G.B., M.S. McAllister, and K. Adury, Drug adjuncts for treating alcohol dependence. Cleve Clin J Med, 2006. 73(7): p. 641-4, 647-8, 650-1, passim.
  49. Brewer, C., How effective is the standard dose of disulfiram? A review of the alcohol-disulfiram reaction in practice. Br J Psychiatry, 1984. 144: p. 200-2.
  50. Drobes, D.J., et al., Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res, 2004. 28(9): p. 1362-70.
  51. Anton, R.F., et al., Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry, 1999. 156(11): p. 1758-64.
  52. Morris, P.L., et al., Naltrexone for alcohol dependence: a randomized controlled trial. Addiction, 2001. 96(11): p. 1565-73.
  53. Mann, K., Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs, 2004. 18(8): p. 485-504.
  54. O'Malley, S.S., et al., Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry, 1996. 53(3): p. 217-24.
  55. Monti, P.M., et al., Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res, 2001. 25(11): p. 1634-47.
  56. Chick, J., et al., United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol, 2000. 35(2): p. 176-87.
  57. Whitworth, A.B., et al., Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet, 1996. 347(9013): p. 1438-42.
  58. Franck, J. and N. Jayaram-Lindstrom, Pharmacotherapy for alcohol dependence: status of current treatments. Curr Opin Neurobiol, 2013. 23(4): p. 692-9.
  59. Peters, S., et al., Differential effects of baclofen and oxytocin on the increased ethanol consumption following chronic psychosocial stress in mice. Addict Biol, 2013. 18(1): p. 66-77.
  60. Warnock, K.T., et al., Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology. Pharmacol Biochem Behav, 2012. 103(1): p. 111-8.
  61. Yang, A.R., et al., Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats. Alcohol Clin Exp Res, 2012. 36(5): p. 863-73.
  62. Edwards, S., et al., Traumatic stress reactivity promotes excessive alcohol drinking and alters the balance of prefrontal cortex-amygdala activity. Transl Psychiatry, 2013. 3: p. e296.
  63. Edwards, S. and G.F. Koob, Experimental psychiatric illness and drug abuse models: from human to animal, an overview. Methods Mol Biol, 2012. 829: p. 31-48.
  64. Maynard, M.E. and J.L. Leasure, Exercise Enhances Hippocampal Recovery following Binge Ethanol Exposure. PLoS One, 2013. 8(9): p. e76644.
  65. Barr, C.S., et al., Functional CRH variation increases stress-induced alcohol consumption in primates. Proc Natl Acad Sci U S A, 2009. 106(34): p. 14593-8.
  66. Becker, H.C., M.F. Lopez, and T.L. Doremus-Fitzwater, Effects of stress on alcohol drinking: a review of animal studies. Psychopharmacology (Berl), 2011. 218(1): p. 131-56.
  67. Tran, T.D., et al., Critical periods for the effects of alcohol exposure on brain weight, body weight, activity and investigation. Behav Brain Res, 2000. 116(1): p. 99-110.
  68. Girard, T.A., et al., Early postnatal ethanol exposure has long-term effects on the performance of male rats in a delayed matching-to-place task in the Morris water maze. Alcohol Clin Exp Res, 2000. 24(3): p. 300-6.
  69. Hartmann, P., et al., Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology, 2013. 58(1): p. 108-19.
  70. Zorzano, A. and E. Herrera, In vivo ethanol elimination in man, monkey and rat: a lack of relationship between the ethanol metabolism and the hepatic activities of alcohol and aldehyde dehydrogenases. Life Sci, 1990. 46(3): p. 223-30.
  71. Nelson, T.J. and D.L. Alkon, Protection against beta-amyloid-induced apoptosis by peptides interacting with beta-amyloid. J Biol Chem, 2007. 282(43): p. 31238-49.
  72. Barua, C.C., et al., Anxiolytic and anticonvulsant activity of methanol extract of leaves of Alternanthera brasiliana (L.) Kuntze (Amaranthaceae) in laboratory animals. Indian J Exp Biol, 2013. 51(6): p. 450-7.
  73. Meyer, E.M., et al., Stress increases voluntary alcohol intake, but does not alter established drinking habits in a rat model of posttraumatic stress disorder. Alcohol Clin Exp Res, 2013. 37(4): p. 566-74.
  74. Litt, M.D., R.M. Kadden, and E. Kabela-Cormier, Individualized assessment and treatment program for alcohol dependence: results of an initial study to train coping skills. Addiction, 2009. 104(11): p. 1837-8.
  75. Kay-Lambkin, F.J., et al., Clinician-assisted computerised versus therapist-delivered treatment for depressive and addictive disorders: a randomised controlled trial. Med J Aust, 2011. 195(3): p. S44-50.


 



fetal-alcohol-syndrome

The Scope of Alcohol-Related Health Problems

Fetal Alcohol Spectrum Disorders

Humanizing Alcohol Research in the United States


   
This site does not provide medical or legal advice. This Web site is for informational purposes only.
Full Disclaimer | Privacy Policy

The Physicians Committee
5100 Wisconsin Ave., N.W., Ste.400, Washington DC, 20016
Phone: 202-686-2210     Email: pcrm@pcrm.org